The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: Oncology nurses' perspectives

Journal of Infusion Nursing

Volumn 30, Issue 3, 2007, Pages 153-160

  Colwell, Hilary H ^a   Mathias, Susan D ^a   Ngo, Nita H ^a   Gitlin, Matthew ^b,c   Lu, Z John ^c   Knoop, Teresa ^c,d,e  

^a Ovation Research Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e Cancer Information Center

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASPARAGINASE; CARBOPLATIN; CETUXIMAB; DIPHENHYDRAMINE; DOCETAXEL; GEMTUZUMAB OZOGAMICIN; OXALIPLATIN; PACLITAXEL; RITUXIMAB; STEROID; TRASTUZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL NURSE SPECIALIST; DISEASE SEVERITY; DRUG INFUSION; FLUID THERAPY; HOSPITAL PATIENT; HUMAN; NURSE; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING PRACTICE; OUTPATIENT; OXYGEN THERAPY; PATIENT INFORMATION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADAPTATION, PSYCHOLOGICAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CONGRESSES; COST OF ILLNESS; DRUG HYPERSENSITIVITY; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; MALE; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; NURSING STAFF; ONCOLOGIC NURSING; OUTPATIENTS; QUALITATIVE RESEARCH; QUESTIONNAIRES; SAFETY MANAGEMENT; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL;

EID: 34249054680     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000270674.13439.5b     Document Type: Article

References (10)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. J Immunol. 2005;174(5):2453-2455.
2. Fiola C. Monoclonal antibodies as anticancer agents [online]. US Pharm. 2003;28(10).
3. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol. 2003;119(4):472-485.
4. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm. 2003;60(15):1531-1548.
5. Rajpal S, Venook AP. Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol. 2006;4(2):124-132.
6. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-471.
7. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72(4):250-256.
8. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 2. Am J Health Syst Pharm. 2003;60(16):1631-1641.
9. Vizcarra C, Belcher D. Management of the patient receiving parenteral biologic therapy. J Infus Nurs. 2006;29(2):63-71.
10. Common Toxicity Criteria, version 3.0. Cancer Therapy Evaluation Program. National Cancer Institute; 2003. Available at: http://ctep.cancer. gov/forms/CTCAEv3.pdf.